Side-by-side comparison of AI visibility scores, market position, and capabilities
Saint Paul MN water treatment and hygiene (NYSE: ECL) $15.7B FY2024 revenue (+5% organic); 25K+ field associates, food safety, data center cooling water treatment opportunity competing with Nalco/Dow and Diversey.
Ecolab Inc. is a Saint Paul, Minnesota-based water treatment, hygiene, and infection prevention company — publicly traded on the New York Stock Exchange (NYSE: ECL) as an S&P 500 Materials component — providing products, equipment, and services for cleaning, sanitizing, water treatment, and infection prevention to food processing plants, restaurants, hotels, hospitals, commercial laundries, power plants, and industrial facilities through approximately 47,000 employees ("associates") in 170 countries. In fiscal year 2024, Ecolab reported revenues of $15.7 billion (+5% organic growth) with record operating income and adjusted diluted EPS growth as the company benefited from pricing actions implemented in 2022-2023 to recover raw material cost inflation, while raw material costs normalized — creating margin expansion on pricing that persisted after input costs declined. CEO Christophe Beck has positioned Ecolab's growth strategy around three secular demand themes: water scarcity (food processing and industrial companies reducing water consumption per unit of output through Ecolab's water recycling and closed-loop treatment chemistry), food safety (food processors and restaurants requiring validated sanitization programs that meet FDA FSMA regulatory requirements for pathogen control), and infection prevention (healthcare facilities requiring hospital-grade disinfectants, surgical scrubs, and environmental hygiene programs that comply with CDC and Joint Commission standards). Ecolab's three divisions — Institutional & Specialty (restaurants, hotels, laundry — $7B+ revenue), Industrial (food processing, beverage, pharma, water treatment — $5B+ revenue), and Healthcare & Life Sciences ($1.5B+ revenue) — serve complementary end markets with differentiated chemistry and service programs.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.